company background image
QNCX logo

Quince Therapeutics NasdaqGS:QNCX Stock Report

Last Price

US$1.13

Market Cap

US$51.4m

7D

-6.6%

1Y

-25.2%

Updated

26 Mar, 2024

Data

Company Financials

Quince Therapeutics, Inc.

NasdaqGS:QNCX Stock Report

Market Cap: US$51.4m

QNCX Stock Overview

Quince Therapeutics, Inc., a preclinical stage biopharmaceutical company, develops precision therapeutics for debilitating and rare diseases.

QNCX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Quince Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Quince Therapeutics
Historical stock prices
Current Share PriceUS$1.13
52 Week HighUS$1.93
52 Week LowUS$0.84
Beta1.27
1 Month Change-15.04%
3 Month Change0.89%
1 Year Change-25.17%
3 Year Change-96.67%
5 Year Changen/a
Change since IPO-96.56%

Recent News & Updates

Recent updates

Here's Why We're Watching Quince Therapeutics' (NASDAQ:QNCX) Cash Burn Situation

Nov 21
Here's Why We're Watching Quince Therapeutics' (NASDAQ:QNCX) Cash Burn Situation

Cortexyme to change name and ticker symbol next month

Jul 27

Cortexyme: A Biotech Worth A Look Based On Potential Alzheimer's Treatment

Mar 01

Cortexyme: Drug Candidate COR588 May Offer Some Hope To Investors

Dec 15

We're Keeping An Eye On Cortexyme's (NASDAQ:CRTX) Cash Burn Rate

Dec 15
We're Keeping An Eye On Cortexyme's (NASDAQ:CRTX) Cash Burn Rate

Cortexyme: A Challenging Path Forward

Nov 17

Cortexyme: Positive Lessons To Be Learned From Disappointing Results

Nov 01

Cortexyme And The Gingipain Hypothesis Of Alzheimer's Disease

Oct 11

Cortexyme: Alzheimer's Readout In November A Binary Event

Sep 12

We Think Cortexyme (NASDAQ:CRTX) Can Afford To Drive Business Growth

Aug 23
We Think Cortexyme (NASDAQ:CRTX) Can Afford To Drive Business Growth

Cortexyme EPS beats by $0.02

May 10

We're Not Very Worried About Cortexyme's (NASDAQ:CRTX) Cash Burn Rate

May 10
We're Not Very Worried About Cortexyme's (NASDAQ:CRTX) Cash Burn Rate

Insider Buying: The Cortexyme, Inc. (NASDAQ:CRTX) Independent Director Just Bought 2.4% More Shares

Mar 10
Insider Buying: The Cortexyme, Inc. (NASDAQ:CRTX) Independent Director Just Bought 2.4% More Shares

Companies Like Cortexyme (NASDAQ:CRTX) Are In A Position To Invest In Growth

Feb 09
Companies Like Cortexyme (NASDAQ:CRTX) Are In A Position To Invest In Growth

Cortexyme: A Fresh Perspective In Alzheimer's

Jan 12

Have Insiders Been Buying Cortexyme, Inc. (NASDAQ:CRTX) Shares This Year?

Dec 18
Have Insiders Been Buying Cortexyme, Inc. (NASDAQ:CRTX) Shares This Year?

Cortexyme weighed down by Citi downgrade

Dec 11

Shareholder Returns

QNCXUS BiotechsUS Market
7D-6.6%-0.5%0.6%
1Y-25.2%9.6%29.5%

Return vs Industry: QNCX underperformed the US Biotechs industry which returned 10.2% over the past year.

Return vs Market: QNCX underperformed the US Market which returned 29.8% over the past year.

Price Volatility

Is QNCX's price volatile compared to industry and market?
QNCX volatility
QNCX Average Weekly Movement7.9%
Biotechs Industry Average Movement11.5%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: QNCX has not had significant price volatility in the past 3 months.

Volatility Over Time: QNCX's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201221Dirk Thyehttps://www.quincetx.com

Quince Therapeutics, Inc., a preclinical stage biopharmaceutical company, develops precision therapeutics for debilitating and rare diseases. Its lead compound is NOV004, a systemically administered bone anabolic peptide engineered to target and concentrate at bone fracture sites. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022.

Quince Therapeutics, Inc. Fundamentals Summary

How do Quince Therapeutics's earnings and revenue compare to its market cap?
QNCX fundamental statistics
Market capUS$51.44m
Earnings (TTM)-US$28.02m
Revenue (TTM)n/a

0.0x

P/S Ratio

-1.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
QNCX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$28.03m
Earnings-US$28.02m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.65
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did QNCX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.